Security
Spyre Therapeutics, Inc. Common Stock · SYRE
SYRENASDAQCommon stockCurrentCIK 1636282Updated Oct 4, 2026
Name history
Aeglea BioTherapeutics, Inc. · through Nov 24, 2023
SYRE price & chart
Loading TradingView…
NASDAQ:SYRE on TradingView ↗In the news
Spyre Therapeutics Announces Grants of Inducement Awards ↗
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares ↗
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update News provided by Spyre Therapeutics, Inc. May 08, 2025, 16:05 ET Share this article Share to X Share this article Share to X On track for mid-year initiations of planned Phase 2 studies in ulcerative coliti ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 777,781,000Source | 608,484,000Source | 341,859,000Source | 71,144,000Source |
| Property, Plant and Equipment, NetUSD | — | — | 0Source | 3,220,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 85,721,000Source | 89,423,000Source | 188,893,000Source | 34,863,000Source |
| Assets, CurrentUSD | 777,781,000Source | 608,474,000Source | 341,528,000Source | 62,258,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 21,248,000Source | 5,386,000Source | 2,251,000Source | 6,172,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 0Source | 3,430,000Source |
| Other Assets, NoncurrentUSD | 0Source | 10,000Source | 9,000Source | 683,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 62,545,000Source | 90,680,000Source | 73,288,000Source | 20,839,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 15,000Source | 13,000Source | 10,000Source | 6,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,127,635,000Source | -972,432,000Source | -764,414,000Source | -425,624,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 869,000Source | 180,000Source | 302,000Source | -48,000Source |
| Stockholders' Equity Attributable to ParentUSD | 715,236,000Source | 517,804,000Source | 184,016,000Source | 50,305,000Source |
| Additional Paid in Capital, Common StockUSD | 1,686,167,000Source | 1,334,223,000Source | 763,191,000Source | 475,971,000Source |
| Liabilities and EquityUSD | 777,781,000Source | 608,484,000Source | 341,859,000Source | 71,144,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 58,685,000Source | 54,060,000Source | 31,978,000Source | 14,656,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 0Source | 625,000Source |
| Accounts Payable, CurrentUSD | — | — | — | 677,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 0Source | 4,004,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | 0Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 756,500,000Source | 603,100,000Source | 339,300,000Source | — |
| Deferred Revenue, CurrentUSD | — | — | — | 517,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | 2,179,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -83,815,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 0Source | 0Source | 744,000Source | 1,567,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 37,614,000Source | 44,833,000Source | 25,675,000Source | 7,111,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | 0Source | -375,000Source | -440,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | -2,641,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -169,252,000Source | -157,410,000Source | -99,910,000Source | -80,144,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -143,475,000Source | -353,285,000Source | -108,393,000Source | 57,008,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 0Source | 0Source | 38,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 309,025,000Source | 410,906,000Source | 361,077,000Source | 42,678,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 0Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,702,000Source | -99,792,000Source | 152,799,000Source | 19,436,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 85,721,000Source | 89,423,000Source | 189,215,000Source | — |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | -15,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 0Source | -3,000Source | 25,000Source | -106,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 756,500,000Source | 603,100,000Source | 339,300,000Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | 10,000,000Source | 0Source | 16,449,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | 0Source | -915,000Source | — |
| General and Administrative ExpenseUSD | 47,909,000Source | 45,776,000Source | 39,946,000Source | 28,531,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | -83,951,000Source |
| Income Tax Expense (Benefit)USD | -15,000Source | 51,000Source | -26,000Source | -136,000Source |
| Net Income (Loss) Attributable to ParentUSD | -155,203,000Source | -208,018,000Source | -338,790,000Source | -83,815,000Source |
| Nonoperating Income (Expense)USD | 54,344,000Source | 599,000Source | -96,513,000Source | 830,000Source |
| Operating ExpensesUSD | 209,562,000Source | 208,566,000Source | 243,189,000Source | 87,110,000Source |
| Other Nonoperating Income (Expense)USD | 29,459,000Source | -20,713,000Source | -19,130,000Source | -7,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 84,555,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | 886,000Source | 2,329,000Source |
| Operating Income (Loss)USD | -209,562,000Source | -208,566,000Source | -242,303,000Source | -84,781,000Source |
| Other Nonoperating Income (Expense)USD | 29,459,000Source | -20,713,000Source | -19,130,000Source | -7,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -155,218,000Source | -207,967,000Source | -338,816,000Source | -83,951,000Source |
| Income Tax Expense (Benefit)USD | -15,000Source | 51,000Source | -26,000Source | -136,000Source |
| Net Income (Loss) Attributable to ParentUSD | -155,203,000Source | -208,018,000Source | -338,790,000Source | -83,815,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 13.76Source | -0.99Source |
| Earnings Per Share, DilutedUSD per share | — | — | 13.76Source | -0.99Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 6,897,065Source | 84,280,785Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 6,897,065Source | 84,280,785Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 47,909,000Source | 45,776,000Source | 39,946,000Source | 28,531,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -155,255,000Source | -207,965,000Source | -338,942,000Source | -84,113,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | -83,951,000Source |
| Investment Income, NetUSD | 24,885,000Source | 21,312,000Source | 6,147,000Source | 837,000Source |
| Nonoperating Income (Expense)USD | 54,344,000Source | 599,000Source | -96,513,000Source | 830,000Source |
| Operating ExpensesUSD | 209,562,000Source | 208,566,000Source | 243,189,000Source | 87,110,000Source |
| Research and Development ExpenseUSD | — | — | — | 58,579,000Source |